ImmunityBio, Inc. - IBRX
About Gravity Analytica
Recent News
- 03.31.2026 - ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline
- 03.26.2026 - ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026
- 03.23.2026 - Goldman Sachs 47th Annual Global Healthcare Conference 2026
- 03.20.2026 - ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors
- 03.19.2026 - 38th Annual ROTH Conference
- 03.17.2026 - ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology have been updated to include ANKTIVA® plus BCG for patients with BCG-unresponsive NMIBC with papillary-only disease
- 03.13.2026 - ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors
- 03.09.2026 - ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data
- 03.04.2026 - The Citizens Life Sciences Conference
- 03.04.2026 - 2026 Jefferies Biotech on the Beach Summit